Teva-Gamida Cell complete enrollment for blood cancer trial
By NEVAGiles23
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and Gamida Cell Ltd. have completed enrollment of 100 patients for their Phase III clinical trial of StemEx, a cell therapy for the treatment of blood cancers, such as leukemia and lymphoma. StemEx is intended for adolescents and adults who cannot find a family related, matched bone marrow donor.
Teva and Gamida Cell are conducting the multi-center international clinical trial through their joint venture, which they own in equal shares. StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted together with the remaining, non-manipulated cells from the same unit.
Gamida Cell president and CEO Dr. Yael Margolin said, “The joint venture is planning to announce the safety and efficacy results of the Phase III StemEx trial in 2012 and to launch the product into the market in 2013. It is our hope that StemEx will provide the answer for the thousands of leukemia and lymphoma patients unable to find a matched, related bone marrow donor.”
Margolin added, ?StemEx may be the first allogeneic cell therapy to be brought to market. This is a source of pride for Gamida Cell, as it further confirms the company?s leadership as a pioneer in cell therapy. In addition to StemEx, Gamida Cell is developing a diverse pipeline of products for the treatment of cancer, hematological diseases such as sickle cell disease and thalassemia, as well as autoimmune and metabolic diseases and conditions helped by regenerative medicine.”
Nochi Dankner's life sciences investment arm Clal Biotechnology Industries Ltd. (TASE: CBI) owns 20% of Gamida Cell and Mordechai Zisser-controlled Elbit Medical Technologies Ltd. (TASE:EMTC) owns 31.6%.
Published by Globes [online], Israel business news – www.globes-online.com – on February 14, 2012
? Copyright of Globes Publisher Itonut (1983) Ltd. 2012
Read the rest here:
URL: http://www.globes.co.il/serveen/globes/docview.asp?did=1000724616
Related Post
- Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective ... - May 16th, 2012
- Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell ... - May 16th, 2012
- TiGenix Reports Business & Financial Results for the First Quarter 2012 - May 16th, 2012
- Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s ... - May 16th, 2012
- Osiris Therapeutics rises following 1Q results - May 13th, 2012
- Stem Cell Therapy Exclusively at Gandy Animal Hospital - Tampa, FL - Video - May 13th, 2012
- In The Know: Stem cell therapy - May 13th, 2012
- Immune Cell Therapy Cures Diabetic Mice, Researchers Find - May 10th, 2012
- Macrocure's CureXcell Shows Strong Efficacy and Safety in Phase IV Hard-To-Heal Wounds Trial - May 10th, 2012
- Pluristem stem cell therapy saves a patient, shares jump - May 10th, 2012
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 6th, 2012
- Stem cell therapy to battle HIV? - May 6th, 2012
- Stem cell therapy for WCMS student has remarkable results - May 6th, 2012
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 2nd, 2012
- Juvenile Parkinson's - Stem cell therapy - Video - May 2nd, 2012
- Genetically modified T cell therapy appears to be safe, lasting in decade-long study of HIV patients - May 2nd, 2012
- Study using stem cell therapy shows promise in fight against HIV - May 2nd, 2012
- Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients - May 2nd, 2012
- Stem cell therapy shows promise in fight against HIV - May 2nd, 2012
- Legendary Texas Football Coach Sam Harrell Returns to Coaching after Stem Cell Therapy at the Stem Cell Institute in ... - April 22nd, 2012
- Stem Cell Therapy Restrictions Debated - April 14th, 2012
- Board considers restricting stem cell therapy - April 14th, 2012
- Texas OKs experimental stem cell therapy limits - April 14th, 2012
- Texas board mulls stem cell therapy restrictions - April 14th, 2012
- Medical board approves controversial adult stem-cell rules - April 14th, 2012
- Texas OKs experimental stem cell therapy rules - April 14th, 2012
- StemCells, Inc's Milestone Clinical Trial in Pelizaeus-Merzbacher Disease Shows Evidence of Myelination Following ... - April 2nd, 2012
- Patient Beware: When Stem Cells Harm - April 2nd, 2012
- NeoStem Announces Proposed Public Offering of Common Stock and Warrants - March 30th, 2012
- Stem cell therapy for the repair of myocardium in heart failure patients - Video - March 30th, 2012
- New gene therapy approach developed for red blood cell disorders - March 28th, 2012
- Cardiac Stem Cell Therapy: Healthy Aging Leader Cenegenics Expands Heart Prevention Program, Joins Optimal Wellness ... - March 28th, 2012
- Cell therapy to improve quality of life - Video - March 27th, 2012
- Midlands Vet Uses Stem Cell Therapy for Pets in Pain - March 27th, 2012
- Cell Therapy Improves Damaged Heart In Study - March 27th, 2012
- Nuvilex Announces Advance in Gene Therapy for Encapsulated Living Cells Using Magnetic Nanoparticles - March 26th, 2012
- Stem cell therapy possibly helpful in heart failure patients - March 26th, 2012
- bone marrow aspiration for stem cell therapy by Dr Adelson - Video - March 25th, 2012
- Doubts cast over effectiveness of bone marrow treatment for heart failure - March 25th, 2012
- Adipose harvest for stem cell therapy by Dr Adelson - Video - March 25th, 2012
a-and-lymphoma , a-single-unit , Biotechnology , elbit-medical , gamida , gamida-cell , into-the-market , itonut , phase , remaining , safety , thousands 
February 15th, 2012
This author published 596 posts in this site.Share
